Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Lutetium Lu 177 Dotatate Yields Partial Responses in Metastatic Bronchopulmonary Neuroendocrine Tumors

September 10th 2025

Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.

FDA Approves Selumetinib for Symptomatic Pediatric NF-1–Associated Inoperable Plexiform Neurofibromas

September 10th 2025

The FDA approved selumetinib granules and capsules for the treatment of pediatric patients at least 1 year of age with NF1 and plexiform neurofibromas.

SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting

September 10th 2025

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

Dr Rathkopf on the Rationale for Evaluating Niraparib Plus Abiraterone Acetate in HRR+ mCSPC

September 9th 2025

Dana E. Rathkopf, MD, discusses the purpose of evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr Monje on the Role of a Novel GD2-Directed CAR T-Cell Therapy in Diffuse Midline Glioma

September 9th 2025

Michelle Monje, MD, PhD, discusses the early efficacy of a novel GD2-directed CAR T-cell therapy for the treatment of children with diffuse midline glioma.

Double-Dose Firmonertinib Showing Promising Activity in First-Line EGFR L858R–Mutated NSCLC

September 9th 2025

Firmonertinib led to responses with a tolerable safety profile in frontline EGFR L858R–mutated NSCLC.

NCCN Adds Dordaviprone to Clinical Practice Guidelines in H3K27M-Mutant Diffuse High-Grade Glioma

September 9th 2025

Dordaviprone was included as a category 2A single agent in the NCCN guidelines for recurrent or progressive H3K27M-mutant diffuse high-grade glioma.

FDA Provides Guidance on Registrational Path for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma

September 9th 2025

The FDA has provided guidance on the design of a potential phase 3 trial evaluating the ADC ozuriftamab vedotin in OPSCC.

Dr Tarantino on the Efficacy of Adjuvant THP in HER2+ Breast Cancer

September 8th 2025

Paolo Tarantino, MD, PhD, discusses the efficacy and safety of adjuvant THP in patients with stage II to IIIA HER2-positive breast cancer.

Dr Gill on the Rationale for Surveying Patients With mCRC About Treatment Decision-Making

September 8th 2025

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses the rationale for evaluating patient experiences and involvement in CRC treatment decision-making.

Dr Nieva on the Role of ADCs in the NSCLC Treatment Paradigm

September 8th 2025

Jorge Nieva, MD, discusses the current role and the effect antibody-drug conjugates have on the lung cancer treatment paradigm.

Dr Popat on the Rationale for Assessing JNJ-5322 in Relapsed/Refractory Myeloma

September 8th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the mechanism of action and the impetus for assessing JNJ-5322 in relapsed/refractory multiple myeloma.

Tepotinib Generates Superior Responses in Adenocarcinoma vs Non-Adenocarcinoma MET Exon 14 Skipping NSCLC

September 8th 2025

Tepotinib showed superior outcomes in patients with adenocarcinoma MET exon 14 skipping NSCLC vs those with non-adenocarcinoma.

Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases

September 8th 2025

Dato-DXd demonstrated CNS PFS and ORR benefits vs docetaxel in patients with NSCLC with brain metastases.

Evolving Options for SCLC Management Drive the Need for Increasingly Personalized Approaches

September 8th 2025

Misty D. Shields, MD, PhD, discusses the importance of approving novel treatments for SCLC and developmental drugs that may challenge the current paradigm.

Ivonescimab Plus Chemo After Third-Generation TKI Generates Improved PFS in EGFR-Mutated NSCLC

September 7th 2025

Ivonescimab plus chemotherapy showed significant and clinically meaningful PFS in EGFR-mutated NSCLC following progression on a third-generation TKI.

Frontline Osimertinib Plus Chemo Significantly Improves OS in EGFR-Mutated Advanced NSCLC

September 7th 2025

Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.

Aumolertinib Plus Chemotherapy Improves PFS in EGFR-Mutated NSCLC

September 7th 2025

The addition of aumolertinib to chemotherapy improved PFS vs aumolertinib monotherapy for the treatment of patients with EGFR-mutated NSCLC.

Dr Shadman on the Impetus for Assessing Zanubrutinib Plus Venetoclax in Previously Untreated CLL/SLL

September 5th 2025

Mazyar Shadman, MD, MPH, details the rationale for investigating the combination of zanubrutinib and venetoclax in treatment-naive CLL/SLL.

Dr Sfakianos on Addressing Unmet Needs With Intravesical Mitomycin in Recurrent, Low-Grade, Intermediate-Risk NMIBC

September 5th 2025

John P. Sfakianos, MD, discusses the rationale for evaluating mitomycin intravesical solution in recurrent, low-grade, intermediate-risk NMIBC.